HC Wainwright Reaffirms Buy Rating for Milestone Pharmaceuticals (NASDAQ:MIST)

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report issued on Monday,Benzinga reports. They currently have a $25.00 target price on the stock. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($0.99) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at $0.02 EPS, FY2028 earnings at $0.46 EPS and FY2029 earnings at $1.86 EPS.

Milestone Pharmaceuticals Price Performance

MIST opened at $2.00 on Monday. The stock has a 50-day moving average price of $1.97 and a 200-day moving average price of $1.67. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The firm has a market cap of $106.66 million, a PE ratio of -2.47 and a beta of 1.78. Milestone Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. Sell-side analysts predict that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of hedge funds have recently bought and sold shares of MIST. Valeo Financial Advisors LLC raised its position in Milestone Pharmaceuticals by 100.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares during the last quarter. Atria Investments Inc raised its position in Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after buying an additional 12,430 shares during the last quarter. BML Capital Management LLC raised its position in Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after buying an additional 33,196 shares during the last quarter. Finally, PVG Asset Management Corp purchased a new position in Milestone Pharmaceuticals in the 3rd quarter worth about $46,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.